title: Should healthy Medicare beneficiaries postpone enrollment in Medicare Part D?
abstract: We compare estimated lifetime out-of-pocket prescription drug expenditures on outpatient prescription drugs, premiums and late enrollment penalties for healthy 65-year-old Medicare beneficiaries if they (a) purchase Part D as soon as they are eligible versus (b) waiting until they contract a drug-intensive condition. Using data from the Medicare Current Beneficiary Survey, a representative sample of the Medicare population, we estimate the annual probability that a healthy 65-year-old will transition to a drug-intensive health state or death. We then use Monte Carlo simulations to estimate expected lifetime prescription drug spending with and without drug insurance. We find that for the statutory minimum benefit policy with a $30 per month premium, lifetime expected expenditures are about 10% higher for women and 6.5% higher for men if healthy beneficiaries postpone enrollment in Part D. Eliminating the late enrollment penalty would create a significant cost advantage for postponed enrollment, particularly for men. Under current rules, the financial advantage of early enrollment coupled with the reduction in risk associated with purchasing Part D plans and potential utility gains from insurance-induced drug consumption, suggests that immediate purchase of Part D is the optimal choice for Medicare beneficiaries.
authors.affiliation: Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA, USA. aatherl@sph.emory.edu
authors.forename: Adam
authors.initials: A
authors.lastname: Atherly
authors.forename: Bryan
authors.initials: B
authors.lastname: Dowd
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care; D003625:Data Collection; D003657:Decision Making; D005260:Female; D005382:Financing, Personal / Q000191:economics*; D006801:Humans; D008297:Male; D054524:Medicare Part D / Q000458:organization & administration / Q000706:statistics & numerical data*; D016134:Organizational Policy; D004364:Pharmaceutical Preparations / Q000191:economics*; D014481:United States
chemical_list: D004364:Pharmaceutical Preparations